NIH funding opportunities

Faculty of Medicine and Health Sciences: Research Development and Support 28 Mei 2018 (#16)

[Click on blue hyperlink for further information]

*The NIH funding opportunities listed below are only a **selection** of pre-screened, currently open health funding opportunities for which **South African institutions are eligible to apply**. For a comprehensive selection of NIH funding opportunities, please visit www.grants.nih.gov.*

Confirm your intent to apply ASAP, but not later than 30 days before the submission date.

Contact: RGMO Pre-Awards cdevries@sun.ac.za

Important Notices:

- **Transition from Inclusion Management System to New Human Subjects System (HSS) as of June 9, 2018 (NOT-OD-18-179)**
- **Notice of Fiscal Policies in Effect for FY 2018 (NOT-OD-18-180)**
- **Notice of Legislative Mandates in Effect for FY 2018 (NOT-OD-18-181)**
- **NIAID Request for Information (RFI): Novel and/or Non-Traditional Influenza Virus Animal Models (NOT-AI-18-038)**
- **Notice of Intent to Publish a Funding Opportunity Announcement for the Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U54) (NOT-CA-18-074) National Cancer Institute**
- **Notice of Intent to Publish a Funding Opportunity Announcement for the Pediatric Immunotherapy Discovery and Development Network (PI-DDN) (U01) (NOT-CA-18-075) National Cancer Institute**
- **Findings of Research Misconduct (NOT-OD-18-183) & (NOT-OD-18-186)**

1. Precision Imaging of Oral Lesions

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-787) (PAR-18-788) **Type:** ***R01*** ***R21***

Application Due Date: Standard dates apply and Standard AIDS dates apply. Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The intent of this Funding Opportunity Announcement (FOA) is to advance the development, adaptation, optimization, and validation of accurate, reproducible, specific, and sensitive imaging approaches to improve diagnosis, treatment, and treatment monitoring for diseases and conditions in the oral cavity and oropharynx.

Budget: R01- Application budgets are not limited but need to reflect the actual needs of the proposed project. The total project period request may not exceed 5 years. R21- Direct costs are limited to $275,000 over a two-year project period, with no more than $200,000 in direct costs allowed in any single year.

2. Genetic analysis of non-human animal models to understand the genomic architecture of substance use disorders and addictive behaviors (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-789) **Type:** ***U01***

Application Due Date: August 21, 2018, March 19, 2019; August 21, 2019, March 19, 2020; August 21, 2020, March 19, 2021, Apply by 5:00 PM local time of applicant organization.

Funding Opportunity Announcement: The goals of this initiative are to discover allelic variants, genomic alterations, and functional changes associated with addictive behaviors in non-human animals through systems studies that employ genetic and genomics strategies. We also encourage applications that take genetic and/or genomics approaches to integrate data, delineate gene networks, and uncover the function of known or newly discovered genetic or epigenetic variants. Investigators examining the phenotype of knockout mice are discouraged from submitting applications to this FOA. Instead, they should submit applications in response PA-17-155 (R01) PA-17-157 (R21) Functional Genetics, Epigenetics, and Non-coding RNAs in Substance Use Disorders." This FOA will replace PAR-15-120 "Identification of Genetic and Genomic Variants by Next-Gen Sequencing in Non-human Animal Models (U01)."

Budget: Application budgets are not limited but need to reflect the actual needs of the proposed project. The maximum project period is 5 years.

3. Development and Testing of Novel Interventions to Improve HIV Prevention, Care, and Program Implementation (Clinical Trial Optional)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PA-18-780) **Type:** ***R34***
Application Due Date: Standard AIDS dates. Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages formative research, intervention development, and pilot-testing of interventions. Primary scientific areas of focus include the feasibility, tolerability, acceptability and safety of novel or adapted interventions that target HIV prevention, treatment or services research. For the purposes of this FOA, "intervention" may include behavioral, social, or structural approaches, as well as combination biomedical and behavioral approaches that prevent the acquisition and transmission of HIV infection, or improve clinical outcomes for persons who are HIV infected.
Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. Direct costs are limited to $450,000 over a three-year period, with no more than $225,000 direct costs allowed in any single year. The maximum period is 3 years.

4. Novel Genomic Technology Development (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-777) **Type:** ***R01***
Application Due Date: October 2, 2018; October 2, 2019; October 2, 2020 **and Aids Dates** January 7, 2019; January 7, 2020; January 7, 2021 Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) seeks grant applications to catalyze major advances in genomics through technology development (beyond developing nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next five to seven years.
Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. An applicant may request direct costs of up to $700,000 per year. The scope of the proposed project should determine the project period. The maximum project period is 4 years.

5. Novel Genomic Technology Development (Clinical Trial Not Allowed)

Letter of Intent: 30 days prior to the application due date **Hyperlink:** (PAR-18-778) **Type:** ***R21***
Application Due Date: October 2, 2018; October 2, 2019; October 2, 2020 and **Aids dates** January 7, 2019; January 7, 2020; January 7, 2021 Apply by 5:00 PM local time of applicant organization.
Funding Opportunity Announcement: This Funding Opportunity Announcement (FOA) encourages grant applications to catalyze major advances in genomics through technology development (beyond developing novel nucleic acid sequencing technologies). The goal is to provide a mechanism for support of very novel and high impact work from across this gamut of genomics technology development. This initiative seeks to support technologies that will have a major impact in the next five to seven years.
Budget: The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications. An applicant may request direct costs of up to $200,000 per year and no more than $400,000 for the entire budget period. Because the nature and scope of the proposed research will vary from application to application, it is anticipated that the size and duration of each award will also vary. The scope of the proposed project should determine the project period. The maximum project period is 3 years.

Brief definitions of some NIH grant mechanisms: ***comprehensive list of extramural grant and cooperative agreement activity codes***